Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5251 AL 5265

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR.

CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.

Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians

Asih PR, Chatterjee P, Verdile G, Gupta VB, Trengove RD, Martins RN.

Neurodegener Dis Manag. 2014;4(5):363-78. doi: 10.2217/nmt.14.29.

Targeting microglia for the treatment of Alzheimer's disease

McGeer PL, McGeer EG.

Expert Opin Ther Targets. 2015 Apr;19(4):497-506. doi: 10.1517/14728222.2014.988707. Epub 2014 Nov 29.

[Diagnosis and treatment of dementia: overview]

Furukawa K, Ishiki A, Tomita N, Arai H.

Rinsho Shinkeigaku. 2014;54(12):1171-3. doi: 10.5692/clinicalneurol.54.1171.

Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?

Borger E, Aitken L, Du H, Zhang W, Gunn-Moore FJ, Yan SS.

Curr Alzheimer Res. 2013 Jan;10(1):21-9.

Alzheimer's disease: recent advances and future perspectives

Ubhi K, Masliah E.

J Alzheimers Dis. 2013;33 Suppl 1:S185-94. doi: 10.3233/JAD-2012-129028.

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study

del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T.

J Alzheimers Dis. 2013;33(1):205-15. doi: 10.3233/JAD-2012-120805.

The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease

Lewis JE, McDaniel HR, Agronin ME, Loewenstein DA, Riveros J, Mestre R, Martinez M, Colina N, Abreu D, Konefal J, Woolger JM, Ali KH.

J Alzheimers Dis. 2013;33(2):393-406. doi: 10.3233/JAD-2012-121381.

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S.

Br J Clin Pharmacol. 2013 May;75(5):1299-311. doi: 10.1111/j.1365-2125.2012.04472.x.

A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease

Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E.

Br J Clin Pharmacol. 2013 May;75(5):1231-9. doi: 10.1111/bcp.12018.

Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure

de Aquino RA, Modolo LV, Alves RB, de Fatima A.

Curr Drug Targets. 2013 Mar;14(3):378-97. doi: 10.2174/138945013804999043.

Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU

Lyseng-Williamson KA, McKeage K.

Drugs Aging. 2013 Jan;30(1):51-8. doi: 10.1007/s40266-012-0041-0.

Tau aggregates as immunotherapeutic targets

Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R.

Front Biosci (Schol Ed). 2013 Jan 1;5(2):426-38. doi: 10.2741/s381.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias